Testosterone metabolism in patients with advanced carcinoma of the prostate: a comparative in vivo study of the effects of oestrogen and antiprolactin
- PMID: 758043
- DOI: 10.1007/BF00261317
Testosterone metabolism in patients with advanced carcinoma of the prostate: a comparative in vivo study of the effects of oestrogen and antiprolactin
Abstract
In the light of the high incidence of cardiovascular side effects with oestrogen therapy in patients with prostatic cancer, other medications altering androgen metabolism are under investigation. The influence of the anti-prolactin bromocriptin (CB157) on plasma kinetics of testosterone and on endogenous hormones was studied and compared with the effect of ethinyl oestradiol in 25 patients with prostatic carcinoma. Bromocriptine significantly suppressed both prolactin and testosterone, inhibited the transfer of androgen from the inner pool into the deep compartment and favoured its degradation. Ethinyl oestradiol decreased testosterone, LH and FSH, and prolonged the biological half-life of testosterone. The effects of bromocriptine on androgen metabolism might be of therapeutic value in patients with prostatic carcinoma.
Similar articles
-
The effects of chlorotrianisene (Tace) of kinetics of 3H-testosterone metabolism in patients with carcinoma of the prostate.Br J Urol. 1982 Aug;54(4):393-8. doi: 10.1111/j.1464-410x.1982.tb08952.x. Br J Urol. 1982. PMID: 6810984
-
Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy.Acta Endocrinol (Copenh). 1976 Feb;81(2):409-26. doi: 10.1530/acta.0.0810409. Acta Endocrinol (Copenh). 1976. PMID: 946155
-
Some effects of treatment with ethinyl oestradiol with or without polyoestradiol phosphate in patients with prostatic carcinoma.Scand J Urol Nephrol. 1986;20(3):193-6. doi: 10.3109/00365598609024493. Scand J Urol Nephrol. 1986. PMID: 3097813
-
Bromocriptine and prostatic carcinoma: plasma kinetics, production and tissue uptake of 3H-testosterone in vivo.J Urol. 1978 Feb;119(2):240-3. doi: 10.1016/s0022-5347(17)57445-5. J Urol. 1978. PMID: 633485
-
Prostatic cancer.Urol Res. 1977;5(1):1-5. doi: 10.1007/BF00257109. Urol Res. 1977. PMID: 324081 Review. No abstract available.
Cited by
-
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.Mol Cancer Ther. 2018 Sep;17(9):1859-1870. doi: 10.1158/1535-7163.MCT-17-1176. Epub 2018 Jun 15. Mol Cancer Ther. 2018. PMID: 29907594 Free PMC article.
-
Drug-induced changes in prolactin secretion. Clinical implications.Med Toxicol Adverse Drug Exp. 1988 Nov-Dec;3(6):463-98. doi: 10.1007/BF03259897. Med Toxicol Adverse Drug Exp. 1988. PMID: 3063922 Review.
-
Understanding the role of dopamine in cancer: past, present and future.Carcinogenesis. 2022 Jun 27;43(6):517-527. doi: 10.1093/carcin/bgac045. Carcinogenesis. 2022. PMID: 35616105 Free PMC article. Review.